Therapeutic gene editing： delivery and regulatory perspectives

Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence- specific engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmacologica Sinica 2017-06, Vol.38 (6), p.738-753
Main Authors: Shim, Gayong, Kim, Dongyoon, Park, Gyu Thae, Jin, Hyerim, Suh, Soo-Kyung, Oh, Yu-Kyoung
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Clustered Regularly Interspaced Short Palindromic Repeats - genetics
Gene Editing
Gene Transfer Techniques
Genetic Therapy
Humans
Immunology
Internal Medicine
Medical Microbiology
Pharmacology/Toxicology
Review
Vaccine
临床试验
交付
展望
性基因
管理
编辑技术
非病毒载体
靶向治疗
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence- specific engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene editing-based therapy is being aggressively developed as a next-generation therapeutic approach to treat a wide range of diseases. However, strategies for precise engineering and delivery of gene-editing nucleases, including zinc finger nucieases, transcription activator-like effector nuclease, and CRISPR/Cas9 （clustered regularly interspaced short palindromic repeats-associated nuclease Cas9）, present major obstacles to the development of gene-editing therapies, as with other gene-targeting therapeutics. Currently, viral and non-viral vectors are being studied for the delivery of these nucleases into cells in the form of DNA, mRNA, or proteins. Clinical trials are already ongoing, and in vivo studies are actively investigating the applicability of CRISPR/Cas9 techniques. However, the concept of correcting the genome poses major concerns from a regulatory perspective, especially in terms of safety. This review addresses current research trends and delivery strategies for gene editing-based therapeutics in non-clinical and clinical settings and considers the associated regulatory issues.
ISSN:1671-4083
1745-7254
DOI:10.1038/aps.2017.2